A paradigm shift in cancer immunotherapy: from enhancement to normalization
MF Sanmamed, L Chen - Cell, 2018 - cell.com
Harnessing an antitumor immune response has been a fundamental strategy in cancer
immunotherapy. For over a century, efforts have primarily focused on amplifying immune …
immunotherapy. For over a century, efforts have primarily focused on amplifying immune …
Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer
PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan… - Cell, 2020 - cell.com
Neoantigens arise from mutations in cancer cells and are important targets of T cell-
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …
[HTML][HTML] Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …
Tumor and microenvironment evolution during immunotherapy with nivolumab
The mechanisms by which immune checkpoint blockade modulates tumor evolution during
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
therapy are unclear. We assessed genomic changes in tumors from 68 patients with …
Melanoma
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of
the disease differ widely across the globe depending on access to early detection and …
the disease differ widely across the globe depending on access to early detection and …
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Background Despite the acknowledged sex-related dimorphism in immune system
response, little is known about the effect of patients' sex on the efficacy of immune …
response, little is known about the effect of patients' sex on the efficacy of immune …
Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis
Importance PD-L1 (programmed cell death ligand 1) immunohistochemistry (IHC), tumor
mutational burden (TMB), gene expression profiling (GEP), and multiplex …
mutational burden (TMB), gene expression profiling (GEP), and multiplex …
Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma
AA Sarnaik, O Hamid, NI Khushalani… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Effective treatment options are limited for patients with advanced (metastatic or
unresectable) melanoma who progress after immune checkpoint inhibitors and targeted …
unresectable) melanoma who progress after immune checkpoint inhibitors and targeted …